Nancy Koch is the founder of Ophirex. Ophirex has raised $37M in total funding. Latest round: Series B. Backed by AXA Investment Managers.
Nancy Koch is the CEO of Ophirex, a biotechnology company based in Corte Madera, California, founded in 2015. Ophirex focuses on developing life-saving antidotes, such as antivenom for snakebites. The company raised $37 million in Series B funding in January 2023, led by AXA Investment Managers, to advance the clinical development and launch of its lead drug candidate, Varespladib. She also serves on the board of directors.
Full founder directory · Investor directory · Company funding database · Fundraising library